Background Quinolones were contraindicated during pregnancy because of concerns regarding fetal malformations and carcinogenesis in animals. The literature is conflicting regarding their safety in humans.
Introduction
The quinolones and their newer derivatives, fluoroquinolones, are highly effective broad-spectrum antibiotics. Their mechanism of action involves the inhibition of bacterial DNA-gyrase and topoisomerase IV. 1 Their excellent pharmacokinetic and bioavailability have made them the drug of choice to treat various systemic and urinary tract infections. 2 The use of fluoroquinolones during pregnancy raised concerns because of their mechanism of action, which involves impaired DNA synthesis that could theoretically cause organ agenesis, mutagenesis, and carcinogenesis in fetal tissues. Several animal model studies have shown possible teratogenic effects. [3] [4] [5] [6] [7] [8] [9] [10] [11] In humans, however, the safety of fluoroquinolones still needs to be elucidated. In 2009, Bar-Oz et al. performed a meta-analysis of the available data regarding the effect of fluoroquinolones, taken during the first trimester, on fetal malformations and pregnancy outcomes. 12 According to their results the use of quinolones during the first trimester of pregnancy does not correlate with an increased risk for major malformations recognised after birth, stillbirths, preterm births, or low birthweight. Although those results seem reassuring, several issues still need to be addressed. First, this metaanalysis examined only first-trimester antibiotic administration. This may cause a bias as underdevelopment, particularly of bone and cartilage, which were evident in animal models, may evolve during the second half of pregnancy. The same argument is relevant for late obstetric complications such as preterm labour. Second, the risk for miscarriages was not evaluated in this metaanalysis. Finally, the quality of the data for some of the included studies was poor because of the very small sample sizes. In 2014 we reviewed the literature regarding the effect of quinolones on animal models as well as in human studies. Whereas in animal models possible teratogenic effects were shown, usually after using very high doses, most of the human studies did not show teratogenic effects or increased risk for unfavourable pregnancy outcomes. 13 In recent years, new data have been published regarding the safety of fluoroquinolones during pregnancy, including high-quality large studies with conflicting results. [14] [15] [16] In the present study we wished to further explore this topic by performing an updated literature search and metaanalysis of the human studies, and in this way provide practical guidance about the use of these agents in pregnancy.
Methods

Sources
We searched Embase, Medline (PubMed and Ovid), ClinicalTrials.gov, Cochrane databases, and the Dart Database using the following keywords: quinolone/s, fluoroquinolone/s, and pregnancy. The search was restricted to English-language journals, studies in humans, and full articles (no abstracts). No additional restrictions were made. All reference lists from the main reports and relevant reviews were hand-searched for additional eligible studies. In addition, we contacted the authors of the included studies for clarifications regarding their results, when needed. The search was updated in August 2017.
Study selection
Studies were included if they examined the association between a quinolone antibiotic and one of the following: fetal malformation/s, miscarriages, stillbirth, or preterm labour. We excluded case reports (n = 50), review articles (n = 126), and data available in abstract form only (n = 2).
Two independent reviewers (EY, MD/PhD and ZN, MD) checked each full-text report for eligibility, and extracted and tabulated all relevant data. Disagreement was settled by consensus among all authors. All procedures conformed to the guidelines for the systematic review and meta-analysis of observational studies in epidemiology (MOOSE) checklist. 17 
Outcomes
The rates of fetal malformations, preterm labour, stillbirth, and miscarriage were analysed. Fetal malformations were evaluated following quinolone exposure at any time during the entire pregnancy, and a second analysis was also performed for exposure during the first trimester only. As not all studies reported on minor malformations, only the major malformations were included. In the other studies we reviewed the malformations list provided and excluded minor malformations. With the lack of consistency in reporting and the small number of cases, chromosomal and genetic aberrations were also excluded.
Live births and fetuses with malformations (stillbirths and those who underwent termination of pregnancy) were included. Stillbirths without knowledge of fetal structure, terminations of pregnancy (induced, elective, and therapeutic), and miscarriages (during either the first trimester or the second trimester, without information on fetal malformations) were excluded from this analysis. In some of the studies that reported on terminations of pregnancy and miscarriages there was no information regarding the trimester (first or second) in which quinolone exposure took place. This information is relevant for the subanalysis of the rate of fetal malformations following quinolone exposure in the first trimester. As most of the exposures occurred in the first trimester, we excluded all cases of terminations of pregnancy and miscarriages from the analysis.
Preterm delivery was defined as delivery prior to 37 weeks of gestation. Only live births were included in this analysis. Stillbirths were considered as any fetal death that occurred after 20 weeks of gestation, except in one study in which stillbirths were defined as fetal death after 23 weeks of gestation.
14 Fetal death prior to that time was considered as miscarriage or termination of pregnancy. The rate of stillbirth was calculated from the total rate of live births and stillbirths. Artificial terminations of pregnancy and miscarriages were excluded from this analysis.
To evaluate the rate of miscarriages we considered quinolone exposures in the first or second trimesters. Artificial terminations of pregnancy were excluded.
Statistical analysis
The analyses were performed in three stages. In the first stage we considered all the studies that included a cohort of women who were prescribed quinolones during pregnancy. The prevalence of the pregnancy outcome (fetal malformation, stillbirth, preterm labour, and miscarriage) was estimated for each study (case-control studies were excluded from this stage). In the second stage of the analyses we calculated a pooled odds ratio (OR) for all of the studies that compared women who were prescribed quinolones against a control group (case-control studies were considered in this stage).
In the third stage, we evaluated the role of several potential sources of heterogeneity by estimating the pooled effects (pooled prevalence, pooled OR) in subgroups: international databases versus national databases; study design (case-control/cohort; relevant for second stage only); and the type of the control group (other antibiotic/no treatment; relevant for second stage only). Quality scores based on the STROBE Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) checklist were evaluated for all of the studies. 18 The maximum possible score was 22, based on 22 items (with partial points given for partial reporting). Quality analyses were performed by examining the association between the effect sizes of outcomes and the quality score using meta-regression.
The heterogeneity of the studies was tested using Cochrane's Q-test of heterogeneity (P < 0.1 was considered statistically significant). Inconsistency in the results of the studies was assessed by I². A random-effects model (DerSimonian and Laird) was chosen if Cochrane's Q-test returned P < 0.1 or I² ≥ 50%. Otherwise, the fixed-effects model (inverse variance method) was chosen. The funnel plot and the Egger test were used to examine publication bias (P < 0.05 was considered a statistically asymmetric funnel plot).
The statistical analysis and graphical presentation were performed using STATA 12.1.
Meta-analyses and review articles are exempt from Institutional Review Board (IRB) approval in our institution.
Results
The study selection process is shown in Figure S1 . Of the 155 abstracts identified, 139 (90%) were excluded for irrelevance. After a full review, 14 studies were deemed eligible according to the inclusion criteria. [14] [15] [16] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The characteristics of these studies are shown in Tables S1 and S2 . Two studies reported data from the same database. 24, 25 We included the updated study in the analysis. 24 Two studies used the same data to report on two different quinolones. 26, 27 We combined the available data from those studies and analysed it only once. Altogether, 13 studies were considered in the meta-analysis. 14, 15, [19] [20] [21] [22] [23] [24] [26] [27] [28] [29] There were nine cohort and four case-control studies. There was heterogeneity in the type of antibiotics studied. Maternal age was reported as a mean value, with or without standard deviation, minimal and maximal age, median and interquartile range, and matched age for the control group. Dependent on the study, the control group was either of pregnant women who did not consume antibiotics during pregnancy or pregnant women who were prescribed antibiotics that are considered to be non-teratogenic.
For each pregnancy outcome (fetal malformations, preterm delivery, stillbirth, and miscarriages) we calculated: the pooled prevalence ( Figure 1) ; the pooled odds ratio (Figure 2 ; Table 1 ); and subgroup analysis of the effect on the results of the quality score (Table 2) , the study design, the type of the control group, and whether the data were from national databases or international databases (Table 2 ). According to the Egger test, no publication bias was detected for any of the outcomes (Table 1) .
Fetal malformations
The pooled prevalence was 5% (95% confidence interval, 95% CI 2.5-7.5%; Q-test for heterogeneity P value < 0.0001; I² = 90.8%) for women who were exposed to quinolone during pregnancy as well as during the first trimester (Figure 1) . When examined in studies with control groups, the rate of fetal malformations was similar between the quinolone group and the control group (Figure 2 ) when quinolones were administered during the first trimester (OR 1.08; 95% CI 0.9-1.29) and during the whole pregnancy (OR 1.08; 95% CI 0.96-1.21). Subgroup analyses did not demonstrate any effect of the quality score (Table 1) , the study design, the type of the control group, or whether the data were from national or international databases (Table 2) .
Preterm delivery
The pooled prevalence of preterm delivery was 7.1% (95% CI 3.3-10.9%) using the random-effects model estimation (Q-test for heterogeneity: P < 0.0001; I² = 83.8%). When examined in studies with control groups the rate of preterm delivery was similar between the quinolone group and controls (Figure 2 ; OR 0.97; 95% CI 0.75-1.24). Subgroup analyses demonstrated that the prevalence of preterm delivery was higher in studies from national databases compared with international databases [9.2% (95% CI 7.2-11.2%) versus 4.2% (95% CI 2.5-5.8%), respectively; Table 2 ]. The rest of the subanalyses did not demonstrate additional effects (Table 2) .
Stillbirth
The pooled prevalence of stillbirth was 0.5% (95% CI 0-1%) with the fixed-effects model estimation (Q-test for heterogeneity: P = 0.182; I² = 38.3%). For stillbirth among women taking quinolones in the first trimester, the pooled prevalence of stillbirth was 0.2% (95% CI 0-0.4%) with fixed-effects model estimation (Q-test for heterogeneity: P = 0.468; I² = 0%). When examined in studies with control groups the rate of stillbirth was similar between the quinolone group and the control group (1.63; 95% CI 0.1-26.5). Subgroup analyses were not performed as only two studies had cases of stillbirth.
Miscarriages
Seven studies reported on miscarriages. The pooled prevalence was 11.2% (95% CI 9.6-12.8%), with fixed-effects model estimation (Q-test for heterogeneity: P = 0.611; I² = 0%), for women who were exposed to quinolones during the first or second trimesters. When examined in studies with control groups the rate of stillbirth was similar between the quinolone group and the control group (OR 1.78; 95% CI 0.93-3.38) with random-effects model estimation (Q-test for heterogeneity: P < 0.0001). The subgroup analyses revealed that for single-country studies, there was no significant association (pooled OR 1.25; 95% CI 0.97-1.59), whereas for the single international study the association was significant (OR 2.41; 95% CI 1.07-5.41; Table 2 ). 23 
Discussion
Main findings
In the present meta-analysis we examined the association between the use of quinolones and obstetric complications. We found no association between quinolone use and increased risk for fetal malformations, preterm delivery, stillbirth, and miscarriage. The risk for miscarriage in the Prevalence (95% CI) % Weight Figure 1 . Forest plot with pooled prevalence of fetal malformations (after quinolone exposure during the whole pregnancy and during the first trimester) and preterm delivery. The random-effects model was used. The odds ratio for miscarriage is not presented because the fixed-effects model was used for this analysis. Stillbirth is not presented as there were just two studies that reported on this outcome. Figure 2 . Forest plot with pooled odds ratios of fetal malformations (after quinolone exposure during the whole pregnancy and during the first trimester) and preterm delivery. The fixed-effects model was used. The odds ratio for miscarriage is not presented because the random-effects model was used for this analysis. Stillbirth is not presented as there were just two studies that reported on this outcome. quinolone group compared with the control group was found to be higher in the study of Loebstein et al., which used international data sources (from Canada, Italy, and the USA), 23 compared with reports of no increased risk in single-country studies. 14, 20, 22 The difference between the results is unclear and might be related to selection bias or genetic factors. Unfortunately, the data do not allow any distinction between first-and second-trimester exposure.
Strengths and limitations
The strengths of this meta-analysis is the incorporation of several high-quality large studies, the analysis of multiple pregnancy outcomes, the use of specific definitions for each pregnancy outcome, and performing multiple subanalyses in order to evaluate reasons for heterogeneity.
There are several limitations to this meta-analysis. First, some of the data come from cohorts of low sample size. Second, the studies are very heterogeneous regarding the source of data, the different definitions for each outcome, the type of control group, and the type of medications examined. In addition, there is not enough available data to allow for analysing the effect of specific medication or specific malformation.
Interpretation
The results of this meta-analysis are consistent with the results of a meta-analysis of five studies performed by BarOz et al. 12 They found that quinolones were not associated with increased risk for major malformations, stillbirths, preterm births, and low birthweight.
Although the overall risk for miscarriage was statistically insignificant, there was an increased risk in the subanalysis of international data sources. There are several possible theories why quinolones can potentially increase the risk for miscarriage. The first reason is the underlying infection that led to the administration of a quinolone prior to the miscarriage. This can explain the results only to some extent, as subanalysis of the studies that compared quinolones with different antibiotics versus no treatment resulted in similar results. An additional explanation is that of direct damage to the developing embryo. This mechanism was shown in animal studies in which members of the quinolone group produced a detectable level of DNA damage in fetal tissues, 5 decreased the number of viable cells, 4 and increased embryolethality. [9] [10] [11] 30, 31 Suggested mechanisms for these complications include single-strand DNA breaks, the inhibition of chondrocyte proliferation, 32 and a reduction in placental-derived progesterone production. 33 It should be noted, however, that most of these complications were witnessed only following the administration of very high doses, and were dependent on the specific antibiotic examined. The third theory may be that the appointment for the condition requiring quinolone therapy itself led to an earlier diagnosis of pregnancy, and that the risk of miscarriage decreases with advancing gestational age. In our opinion, until further information from large studies become available regarding the safety of quinolones in the first trimester, these antibiotics should not be used as a first-line therapy during that time.
In this meta-analysis the rate of preterm births was similar between the quinolone group and the control group; however, when examined separately, the rate of preterm births was higher in studies from national databases compared with international databases. This result is attributed mainly to the study of Berkovitch et al., which demonstrated a 19% prevalence of preterm births in the quinolone group. 20 This high rate might be an effect of the small sample size in this study, and also the relatively higher rate of preterm births in Canada. 34 
Conclusion
Altogether, while considering the limitations mentioned above, the results of this meta-analysis demonstrated that quinolones are not associated with unfavourable pregnancy outcomes, including increased risk for fetal malformation. The available information in the literature is limited, however; therefore, this antibiotic should not be used as a firstline therapy during the first trimester until further data are available. Nevertheless, for continuing pregnancies, there is no further risk for other unfavourable pregnancy outcomes, including fetal malformations.
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